Summary
Current concepts in the treatment of psoriasis are reviewed, including: traditional modalities ofdithranol (anthralin), tar, and corticosteroids alone or in combination with other agents; phototherapy and photochemotherapy; experimental studies with the aromatic retinoid etretinate and related analogues; dialysis; and the potential use of hyperthermia. Prudent administration of agents that are known to have serious side effects should be the concern of all clinicians. Many regimens that have beneficial short term results may have the potential for long term sequelae that may not only affect the patient but the offspring as well.
Two of the most promising innovative concepts in the therapeutic armamentarium for psoriasis are psoriasis ‘day care centres’, and prevention and self care. With the everincreasing costs of medical care throughout the world, ways and means of reducing costs should be initiated by the clinician when considering a treatment programme. The clinician has the responsibility of determining whether the severity of the disease warrants ambulatory outpatient regimens or hospitalisation. If the patient would benefit from daily attention, then the psoriasis day care centre approach provides an appropriate clinical setting. However, in addition to administering appropriate medication, it is incumbent upon the clinician to educate patients regarding their disease and the triggering factors to prevent exacerbations.
‘Disability prevention’ means extending the services of clinicians and others to deal systematically with 2 areas involved in disease development; one is recognising the genetic component of psoriasis; the other, environmental triggering factors, e.g. infection, trauma to the skin, low humidity, and stress. Until recently, dermatology has focused on diseases and repairing the damage they cause. Now, the significance of genetic and environmental influences in multifactorial diseases like psoriasis has been realised, as has the importance of educating psoriasis patients to understand their disease and to encourage them to take responsibility for self-care so that the morbidity will be lessened.
Similar content being viewed by others
References
Abel, E.A.: Lithium: Literature review. International Psoriasis Bulletin 10: 3 (1983).
Abel. E.A.; Cox, A.J. and Farber, E.M.: Epidermal dystrophy and actinic keratoses in psoriasis patients following oral psoralen photochemotherapy (PUVA): Follow-up study. Journal of the American Academy of Dermatology 7: 333–340 (1982).
Ashton. R.E.: Andre, P.; Lowe, N.J. and Whitefield, M: Anthralin: Historical and current perspectives. Journal of the American Academy of Dermatology 9: 173–192 (1983).
Ashton, R.E.; Millward-Sadler, G.H. and White, J.E.: Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. Journal of Investigative Dermatology 79: 229–232 (1982).
Baker, H.: Antimitotic drugs in psoriasis; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.120–123 (Grune and Stratton, New York 1982).
Baker, H.; Seville, R.H. and Warin, A.P.: 0.5% dithranol cream in the treatment of psoriasis. Clinical and Experimental Dermatology 6: 119–120 (1981).
Belsito, D.V. and Kechijian, P.: The role of tar in Goeckerman therapy. Archives of Dermatology 118: 319–321 (1982).
Bickers, D.R.: The carcinogenicity and mutagenicity of therapeutic coal tar —a perspective. Journal of Investigative Dermatology 77: 173–174 (1981).
Bollag. W.: Prophylaxis of chemically induced benign and malignant epithelial tumors by vitamin A acid (retinoic acid). European Journal of Cancer 8: 689–693 (1972).
Bollag. W.: Therapeutic effects of an aromatic retinoic acid analog on chemically induced skin papillomas and carcinomas of mice. European Journal of Cancer 10: 731–737 (1974).
Bollag. W.: Chemistry and pharmacology of retinoids; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp. 175–183 (Grune and Stratton, New York 1982).
Brandt. H. and Mustakallio. K.K.: Irritation and staining by dithranol (anthralin) and related compounds: III. Cumulative irritancy and staining during repeated chamber testing. Acta Dermato-Vcnereologica (Stockholm) 63: 237–240 (1983).
BrifTa. D.V.: Rogers, S.: Greaves, M.W.; Marks. J.: Shuster. S. and Warin. A.P.: A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clinical and Experimental Dermatology 3: 339–347 (1978).
Brody. I. and Johansson. A.: A topical treatment program for psoriasis with low anthralin concentrations. Journal of Cutaneous Pathology 4: 233–243 (1977).
Clark. D.W. and MacMahon. B. (Eds): Prevention and Community Medicine (Little, Brown and Company. Boston 1981).
Comaish. J.S.: Tar and related compounds in the therapy of psoriasis. Clinical and Experimental Dermatology 6: 639–645 (1981).
Convit, J.: Investigation of the incidence of psoriasis among Latin American Indians; in Pillsbury and Livingood (Eds) Proceedings of the XII International Congress of Dermatology, International Congress Series No. 55, pp.196–199 (Excerpta Mcdica Foundation. New York 1963).
Cox. A.J. and Abel. E.A.: Epidermal dystrophy. Occurrence after psoriasis therapy with psoralen and long-wave ultraviolet light. Archives of Dermatology 115: 567–579 (1979).
Cram, D.L.: Psoriasis day care center. International Journal of Dermatology 14: 577–578 (1975).
Cram, D.L.: Psoriasis: Treatment with a tar gel. Cutis 17: 1197–1203 (1976).
Cripps, D.J. and Lowe, N.J.: Photochemotherapy for psoriasis, remission times, and combined photo-chemotherapy with anthralin. Clinical and Experimental Dermatology 4: 477–484 (1979).
Cyrlin, M.N.; Pedois-Leftick, A. and Sugar, J.: Cataract formation in association with ultraviolet photosensitivity. Annals of Ophthalmology 12: 786–790 (1980).
Dahl, B.; Mollenbach, K. and Reymann, F.: Treatment of psoriasis with a new retinoic acid derivative Ro 10-9359. Dermatologica 154: 261–267 (1977).
DesGroseilliers, J.P.; Cullen, A.E. and Rouleau, G.A.: Ambulatory Goeckerman treatment of psoriasis: Experience with 200 patients. Canadian Medical Association Journal 124: 1018–1020 (1981).
Ehmann, C.W. and Voorhees, J.J.: International studies of the efficacy of etretinate in the treatment of psoriasis. Journal of the American Academy of Dermatology 6: 692–696 (1982).
Epstein, J.H.; Farber, E.M.; Nall, L. et al.: Current status of oral PUVA therapy for psoriasis. Journal of the American Academy of Dermatology 1: 106–117 (1979).
Farber, E.M.: Anthralin; in Swanbeck (Ed.) Proceedings of the International Conference on Patient Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984a).
Farber, E.M.: Psoriasis: A worldwide disease; in Swanbeck (Ed.) Proceedings of the International Conference on Patient Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984b).
Farber, E.M. and Abel, E.A.: Psoriasis; in Rubenstein and Federman (Eds) Scientific American Medicine, Vol. 1, pp. 1–13 (Scientific American, New York 1983).
Farber, E.M.; Abel, E.A. and Charuworn, A.: Recent advances in the treatment of psoriasis. Journal of the American Academy of Dermatology 8: 311–321 (1983b).
Farber, E.M.; Abel, E.A. and Nall, L.: An evaluation of advances in the therapy of psoriasis; in Kukita and Seiji (Eds) Proceedings of the XVIth International Congress of Dermatology, May 23–28, 1982, pp.81–85 (University of Tokyo Press, Tokyo 1983a).
Farber, E.M. and Cox, A.J. (Eds): Psoriasis. Proceedings of the International Symposium, Stanford University 1971 (Stanford University Press, Stanford 1971).
Farber, E.M. and Cox, A.J. (Eds): Psoriasis. Proceedings of the Second International Symposium (Yorke Medical Books, New York 1977).
Farber, E.M. and Cox, A.J. (Eds): Psoriasis. Proceedings of the Third International Symposium (Grune and Stratton, New York 1982).
Farber, E.M.; Cox, A.J.; Jacobs, P.H. and Nall, L. (Eds): Psoriasis Day Care Center. International Psoriasis Bulletin 1(3): 1–6 (1974b).
Farber, E.M.; Epstein, J.H.; Nall, L. et al.: Current status of oral PUVA therapy for psoriasis: Eye protection revisions. Journal of the American Academy of Dermatology 6: 851–855 (1982).
Farber, E.M. and Harris, D.H.: Hospital treatment of psoriasis. A modified anthralin program. Archives of Dermatology 101: 381–389 (1970).
Farber, E.M.; Jacobs, J.H.; Cox, A.J. and Nall, L. (Eds): Crude coal tar. International Psoriasis Bulletin 4(4): 1–6 (1977).
Farber, E.M. and Nall, L.: Innovative uses of anthralin: An overview of past, present, and future developments. British Journal of Dermatology 105 (Suppl. 20): 111–114 (1981a).
Farber, E.M. and Nall, L.: The use of oral aromatic retinoids in psoriasis therapy: An overview of past, present, and future developments; in Orfanos et al. (Eds) Retinoids. Advances in Basic Research and Therapy, pp. 515–519 (Springer, Berlin 1981b).
Farber, E.M. and Nall, L.: Epidemiology in psoriasis research. Hawaii Medical Journal 41: 430–442 (1983a).
Farber, E.M. and Nall, L.: Etiology and pathogenesis of psoriasis: An overview; in Kukita and Seiji (Eds) Proceedings of the XVIth International Congress of Dermatology, May 23–28, 1982, pp.363–380 (University of Tokyo Press, Tokyo 1983b).
Farber, E.M. and Nall, L.: An appraisal of measures to prevent and control psoriasis. Journal of the American Academy of Dermatology 10: 511–517 (1984a).
Farber, E.M. and Nall, L: Epidemiology of psoriasis: Natural history and genetics, Chapter 2; in Roenigk and Maibach (Eds) Textbook on Psoriasis (Marcel Dekker, New York; in press 1984b).
Farber, E.M. and Nall, M.L.: The natural history of psoriasis in 5,600 patients. Dermatologica 148: 1–18 (1974).
Farber, E.M.; Nall, L. and Strefling, A.: Psoriasis —a disease of the total skin. Journal of the American Academy of Dermatology (In press, 1984).
Farber, E.M.; Roth, R.J.; Aschheim, E. et al.: Role of trauma in isomorphic response in psoriasis. Archives of Dermatology 91: 246–251 (1965).
Farber, E.M.; Wolf, P.L.; Nall, M.L.; Kurtis, B.W. and Bennett, R.G.: Relationship between psoriasis and arthritis; in Flarer et al. (Eds) Proceedings of the XIVth International Congress of Dermatology, Padua/Venice, 1972, pp.493–498 (American Elsevier, New York 1974a).
Frederiksson, T.: Topical treatment of psoriasis with 5-fluorouracil and fluocinolone acetonide; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp. 399–400 (Grune and Stratton, New York 1982).
Fritsch, P.O.; Hönigsmann, H.; Jaschke, E. and Wolff, K.: Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic derivative. Journal of Investigative Dermatology 70: 178–182 (1978).
Frost, P.; Horwitz, S.N.; Capato, R.V. and Berger, S.M.: Tar gelphototherapy for psoriasis. Archives of Dermatology 115: 840–846 (1979).
Gay, M.W.; Morre, W.J.; Morgan, J.M. and Montes, L.F.: Anthralin toxicity. Archives of Dermatology 105: 213–215 (1972).
Glazer, S.K.; Roenigk Jr, H.H.; Yokoo, H. and Sparberg, M.: A study of potential hepatotoxicity of etretinate used in the treatment of psoriasis. Journal of the American Academy of Dermatology 6: 683–687 (1982).
Glew, W.B.: Determination of 8-methoxypsoralen in serum, aqueous, and lens: Relation of long-wave ultraviolet toxicity in experimental and clinical photochemotherapy. Transactions of the American Ophthalmological Society 77: 464–514 (1979).
Glinski, W.; Jablonska, S.; Imiela, J.; Nosarzewski, J.; Jarzabek-Chorzelska, M.; Haftek, M. and Obalek, S.: Continuous peritoneal dialysis for treatment of psoriasis. I. Depletion of PMNL as a possible factor for clearing of psoriatic lesions. Archives of Dermatological Research 265: 337–341 (1979a).
Glinski, W.; Jablonska, S.; Jarzabek-Chorzelska, M; Zarebska, Z.; Imiela, J. and Nosarzewski, J.: Continuous peritoneal dialysis for treatment of psoriasis. II. Destruction of stratum corneum with peritoneal PMNL serine proteinase. Archives of Dermatological Research 266: 83–86 (1979b).
Goeckerman, W.H.: Treatment of psoriasis. Northwest Medicine 24: 229–231 (1925).
Goerz, G. and Orfanos, C: Systemic treatment of psoriasis with a new aromatic retinoid. Dermatologica 157 (Suppl. 1): 38–44 (1978).
Goldberg, L.H.; Schaefer, H. and Farber, E.M.: PUVA and the eye. Journal of Investigative Dermatology 72: 278 (1979).
Goransson, A.M.; Kolari, P.J. and Mustakallio, K.K.: Irritation and staining by dithranol (anthralin) and related compounds: V. Short contact and tape stripping experiments with dithranol and butantrone. Acta Dermato-Venereologica (Stockholm) (In press 1984).
Grupper, C: The chemistry, pharmacology, and the use of tar in psoriasis; in Farber and Cox (Eds) Psoriasis. Proceedings of the International Symposium, Stanford University, 1971, pp.347–356 (Stanford University Press, Stanford 1971).
Gunawardena, D.A.; Gunawardena, K.A.; Vasanthanathan, N.S. and Gunawardena, J.A.: Psoriasis in Sri Lanka —a computer analysis of 1,366 cases. British Journal of Dermatology 98: 85–96 (1978).
Halevy, S.; Halevy, J.; Boney, G.; Rosenfeld, J.B. and Feuerman, E.J.: Dialysis therapy for psoriasis. Report of three cases and review of the literature. Archives of Dermatology 117: 69–72 (1981).
Hanno, R.; Gruber, G.G.; Owen, L.G. and Callen, J.P.: Methotrexate in psoriasis. A brief review of indications, usage, and complications of methotrexate therapy. Journal of the American Academy of Dermatology 2: 171–174 (1980).
Hansen, N.E.: Development of acute myeloid leukemia in a patient with psoriasis treated with oral 8-methoxypsoralen and longwave ultraviolet light. Scandinavian Journal of Haematology 22: 57–60 (1979).
Hellier, F.F. and Whitefield, M.: The treatment of psoriasis with triacetoxyanthracene. British Journal of Dermatology 79: 491–496 (1967).
Henan Dermatoses Survey Group: An analysis of 487 cases of psoriasis in 100,000 natural population of Henan rural district. Chinese Journal of Dermatology 15: 83–84 (1982).
Hulsebosch, H. and Ponec-Waelsch, M.: The interaction of anthralin, salicylic acid and zinc oxide in pastes. Dermatologica 144: 287–293 (1972).
Ingram, J.T.: Approach to psoriasis. British Medical Journal 2: 591–594 (1953).
Ingram, J.T.: The significance and management of psoriasis. British Medical Journal 2: 823–828 (1954).
Juhlin, L.: Factors influencing anthralin erythema. British Journal of Dermatology 105 (Suppl. 20): 87–90 (1981).
Kenney, J.: Psoriasis in the American Black; in Farber and Cox (Eds) Psoriasis. Proceedings of the International Symposium, Stanford University, 1971, pp.49–51 (Stanford University Press, Stanford 1971).
Kragballe, K.; Zachariae, E. and Zachariae, H.: Methotrexate in psoriatic arthritis: A retrospective study. Acta Dermato-Venereologica (Stockholm) 63: 165–167 (1982).
Kraning, K.K. and Odland, G.F.: Prevalence, morbidity and costs of dermatological diseases. Journal of Investigative Dermatology 73: 395–401 (1979a).
Kraning, K.K. and Odland, G.F.: I. Psoriasis. Journal of Investigative Dermatology 73: 402–413 (1979b).
Larko, O. and DifTey, B.L.: Natural UV-B radiation received by people with outdoor, indoor, and mixed occupations and UVB treatment of psoriasis. Clinical and Experimental Dermatology 8: 279–285 (1983).
Larko, O. and Swanbeck, G.: Psoriasis treatment and a day-care centre: Clinical aspects and an attempt at a cost-benefit analysis. Acta Dermato-Venereologica (Stockholm) 62: 413–418 (1982).
Lauharanta, J.; Juvakoski, T.; Kanerva, L. and Lassus, A.: Combination of etretinate and PUVA: A new effective way to treat psoriasis; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.499–500 (Grune and Stratton, New York 1982).
Leavell, U.W.; Yarbro, J.W.: Treatment of psoriasis by hydroxyurea. Southern Medical Journal 64: 1253–1255 (1971).
Lerman, S. and Borkman, R.F.: A method for detecting 8-methoxypsoralen in the ocular lens. Science 197: 1287–1288 (1977).
Lerman, S.; Egaw, J. and Willis, I.: Potential ocular complications for PUVA therapy and their prevention. Journal of Investigative Dermatology 74: 197–199 (1980).
Levine, M.J.; White, H.A.D. and Parrish, J.A.: Components of the Goeckerman regimen. Journal of Investigative Dermatology 10: 455–459 (1979).
Lindgren, S. and Groth, O.: Generalized pustular psoriasis. A report of thirteen patients. Acta Dermatovenereologica 56: 139–147 (1976).
Lomholt, G.: Psoriasis: Prevalence, spontaneous course and genetics. A census study on the prevalence of skin diseases on the Faroe Islands, (GEC GAD, Copenhagen 1963).
Lowe, N.J. and Breeding, J.: Anthralin —different concentration effects on epidermal cell DNA synthesis rates in mice and clinical responses in human psoriasis. Archives of Dermatology 117: 698–700 (1981).
Lowe, N.J.; Breeding, J. and Wortzman, M.S.: The pharmacological variability of crude coal tar. British Journal of Dermatology 107: 475–480 (1982a).
Lowe, N.J.; Breeding, J.H. and Wortzman, M.S.: New coal tar extract and coal tar shampoos. Evaluation by epidermal cell DNA synthesis suppression assay. Archives of Dermatology 118: 487–489 (1982b).
Lowe, N.J.; Wortzman, M.S.; Breeding, J.; Koudsi, H. and Taylor, L.: Coal tar phototherapy for psoriasis re-evaluated. Journal of the American Academy of Dermatology 8: 781–789 (1983).
Maibach, H.I.: Corticosteroids; in Swanbeck (Ed.) Proceedings of the Conference on Psoriasis Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984).
Mayer, H.; Bollag, W.; Hanni, R. and Ruegg, R.: Retinoids, a new class of compounds with prophylactic and therapeutic activities in oncology and dermatology. Experientia 34: 1105–1119 (1978).
Moller, H.: A case for and against intermittent therapy; in Swanbeck (Ed.) Proceedings of the Conference on Psoriasis Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984).
Montes, L.F.; Wilborn, W.H. and Brody, I.: Low strength anthralin in psoriasis. Journal of Cutaneous Pathology 6: 445–456 (1979).
Morhenn, V.B.; Benike, C.J. and Engelman, E.G.: Inhibition of cell mediated immune response by 8-methoxypsoralen and long-wave ultraviolet light: A possible explanation for clinical effects of photo-activated psoralen. Journal of Investigative Dermatology 75: 249–252 (1980).
Morison, W.L.; Parrish, J.A. and Fitzpatrick, T.B.: Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. British Journal of Dermatology 98: 125–132 (1978).
Muller, S.A.; Perry, H.O.; Pittelkow, M.R.; Maughan, W.Z. and O’Brien, P.C.: Coal tar, ultraviolet light, and cancer. Journal of the American Academy of Dermatology 4: 234–235 (1981).
Mustakallio, K.K.: Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography. Acta Dermato-Venereologica (Stockholm) 59 (Suppl. 85): 125–132 (1979).
Mustakallio, K.K.: Irritation and staining by dithranol (anthralin) and related compounds: II. Structure-activity relationships among 10-meso-substituted acyl analogues. Acta Dermato-Venereologica (Stockholm) 60: 169–171 (1980).
Mustakallio, K.K.: How to reduce irritation and staining; the side effects of dithranol treatment; in Swanbeck (Ed.) Proceedings of the International Conference on Patient Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984).
Mustakallio, K.K. and Kolari, P.J.: Irritation and staining by dithranol (anthralin) and related compounds: IV. Visual estimation of erythema compared with contact thermometry and laser Doppler flowmetry. Acta Dermato-Venereologica (Stockholm) (In press 1984).
Nyfors, A.: Liver biopsies from psoriatics related to methotrexate therapy. Acta Pathologica et Microbiologica Scandinavica, Section A: Pathology 85: 511–518 (1977).
Orenberg, E.K.; Deneau, D.G. and Farber, E.M.: Response of chronic psoriatic plaques to localized heating induced by ultrasound. Archives of Dermatology 116: 893–897 (1980).
Orenberg, E.K.; Deneau, D.G.; Pounds, D. et al.: Treatment of chronic psoriatic plaque with hyperthermia induced by ultrasound; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.345–346 (Grune and Stratton, New York 1982).
Orfanos, C. and Runne, U.: Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis. British Journal of Dermatology 95: 101–103 (1976).
Orfanos, C.E.: Oral administration of retinoids. Dermatologica 157 (Suppl. 1): 2–4 (1978).
Orfanos, C.E.: Oral retinoids —present status. British Journal of Dermatology 103: 473–481 (1980).
Orfanos, C.E.: Oral retinoid in psoriasis: Current clinical experiences and possible mechanisms of action; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp. 197–209 (Grune and Stratton, New York 1982).
Orfanos, C.E.; Braun-Falco, O.; Farber, E.M.; Grupper, Ch.; Polano, M.K. and Schuppli, R. (Eds): Retinoids. Advances in basic research and therapy (Springer, Berlin 1981).
Orfanos, C.E.; Steigleder, G.; Pullmann, H. and Black, P.H.: Oral retinoid and UVB radiation. A new alternative treatment for psoriasis on an outpatient basis. Acta Dermato-Venereologica (Stockholm) 59: 241–244 (1979).
Parrish, J.A.: Action spectrum for phototherapy of psoriasis. Journal of Investigative Dermatology 76: 359–362 (1981a).
Parrish, J.A.: Phototherapy and photochemotherapy of skin diseases. Journal of Investigative Dermatology 77: 167–171 (1981b).
Parrish, J.A.: UVB phototherapy —mechanisms, techniques, and perspectives; in Swanbeck (Ed.) Proceedings of the International Conference on Patient Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984).
Parrish, J.A.; Fitzpatrick, T.B.; Tanenbaum, L. and Pathak, M.A.: Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. New England Journal of Medicine 291: 1207–1211 (1974).
Perry, H.O.; Soderstrom, C.W. and Schultz, R.W.: The Goeckerman treatment of psoriasis. Archives of Dermatology 112: 1249–1250 (1976).
Petrozzi, J.W.: Do topical steroids help in treatment of psoriasis with UVL? in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.421–422 (Grune and Stratton, New York 1982).
Petrozzi, J.W.: Topical steroids and UV radiation in psoriasis. Archives of Dermatology 119: 207–210 (1983).
Petrozzi, J.W. and Barton, J.O.: Comparison of crude coal tar and topical methoxsalen in treatment of psoriasis. Archives of Dermatology 115: 1061–1063 (1979).
Petrozzi, J.W.; Barton, J.O.; Kaidbey, K.H. and Kligman, A.M.: Updating the Goeckerman regimen for psoriasis. British Journal of Dermatology 98: 437–444 (1978).
Petrozzi, J.W. and Kligman, A.L.: Tar and phototherapy. Journal of Investigative Dermatology 71: 280 (1979).
Pittelkow, M.R.; Perry, H.O.; Muller, S.A.; Maughan, W.Z. and O’Brien, P.C.: Skin cancer in patients with psoriasis treated with coal tar. Archives of Dermatology 117: 465–468 (1981).
Polano, M.E.; van der Rhee, H.J. and van der SchroefT, J.G.: Treatment of psoriasis with oral etretinate and topical corticosteroids; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.497–498 (Grune and Stratton, New York 1982).
Pullmann, H.; Zingheim, M; Steigleder, G. and Orfanos, C: PUVA-und Anthralin-Therapie der Psoriasis ein Klinischer, Histologischer und Autoradiographischer Vergleich. Zeitschrift Fur Hautkrankheiten 51: 861–871 (1976).
Ramsey, D.L. and Fox, A.B.: Ability of primary care physicians to recognize the common dermatoses. Archives of Dermatology 117: 620–622 (1981).
Rea, J.N.; Newhouse, M.L. and Halil, T.: Skin disease in Lambeth: A community study of prevalence and use of medical care. British Journal of Preventive and Social Medicine 30: 107–114 (1976).
Roenigk, H.H.; Maibach, H.I. and Weinstein, G.: Use of methotrexate in psoriasis. Archives of Dermatology 105: 363–365 (1972).
Roenigk, H.H.; Maibach, H.I. and Weinstein, G.: Methotrexate therapy for psoriasis. Archives of Dermatology 108: 35 (1973).
Roenigk, H.; Auerbach, R.; Maibach, H. and Weinstein, G.: Methotrexate guidelines —revised. Journal of the American Academy of Dermatology 6: 145–155 (1982).
Roenigk, H.H.; Farber, E.M.; Storrs, F. et al.: Photochemotherapy for psoriasis: A clinical cooperative study of PUVA-48 and PUVA-64. Archives of Dermatology 115: 576–579 (1979).
Rogers, S.; Marks, J.; Shuster, S.; Briffa, V.D.; Warin, A. and Greaves, M.: Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1: 455–458 (1979).
Runne, U. and Kunze, J.: Short-duration (‘minutes’) therapy with dithranol for psoriasis: A new outpatient regimen. British Journal of Dermatology 106: 135–139 (1982).
Saperstein, M.D. and Wheeler, L.A.: Mutagenicity of coal tar preparations used in the treatment of psoriasis. Toxicology Letters 3: 325–329 (1979).
Schaefer, H. (Ed.): Proceedings of Symposium on Current Concept in the Mode of Action of Anthralin in the Treatment of Psoriasis, Sophia Antipolis, France, October 17–18, 1980. British Journal of Dermatology 105 (Suppl. 20) [1981].
Schaefer, H.; Farber, E.M.; Goldberg, L. and Schalla, W.: Limited application period for anthralin in psoriasis: Preliminary report on penetration and clinical efficacy. British Journal of Dermatology 102: 571–573 (1980).
Schaefer, H.; Schalla, W. and Schroot, B.: Pharmacology and kinetics of anthralin; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.111–118 (Grune and Stratton, New York 1982).
Schaefer, H. and Mustakallio, K.K.: Dithranol (anthralin) and related anti-psoriatic compounds; in Kukita and Seiji (Eds) Proceedings of the XVIth International Congress of Dermatology, May 23–28, 1982, pp.605–607 (University of Tokyo Press, Tokyo 1983).
Schillinger, B. and Brody, N.: Acanthoma induction in psoriasis patients after short-term high potency Goeckerman treatment. Cutis 28: 568–570 (1981).
Schweicker, R.S.: Disease prevention and health promotion. Journal of Medical Education 57: 15–19 (1982).
Segal, A.; Katz, C. and Van Duuren, B.L.: Structure and tumorpromoting activity of anthralin (l,8-dihydroxy-9-anthrone) and related compounds. Journal of Medicinal Chemistry 14: 1152–1154 (1971).
Seville, R.H.: Simplified dithranol treatment of psoriasis. British Journal of Dermatology 93: 205–208 (1975).
Seville, R.H.: Advances in the use of anthralin. Journal of the American Academy of Dermatology 5: 319–321 (1981).
Seville, R.; Walker, G. and Whitefield, M.: Dithranol cream. British Journal of Dermatology 100: 475–476 (1979).
Stern, R.S.; Thibodeau, L.A.; Kleinerman, R.A.; Parrish, J.A.; Fitzpatrick, T.B. et al.: Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. New England Journal of Medicine 300: 809–813 (1979).
Stern, R.S.; Zierler, S. and Parrish, J.A.: Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1: 732–735 (1980).
Stern, R.S.; Zierler, S. and Parrish, J.A.: Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 50: 869–872 (1982).
Stoughton, R.B.: Evaluation of new potent steroids; in Gomez and Zaias (Eds) Recent Advances in Dermatopharmacology, pp.105–112 (Spectrum, New York 1975).
Stoughton, R.B.: Azone™ enhances percutaneous penetration; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.397–398 (Grune and Stratton, New York 1982).
Swanbeck, G. (Ed): Proceedings of the International Conference on Patient Care, Gothenburg, Sweden, August 28–31, 1983 (In press 1984).
Tanenbaum, L.; Parrish, H.A.; Pathak, M.A.; Anderson, R.R. and Fitzpatrick, T.B.: Tar phototoxicity and phototherapy for psoriasis. Archives of Dermatology 111: 467–470 (1975).
van de Kerkhof, P.C.M. and Mali, J.W.H.: Methotrexate maintenance following Ingram therapy in ‘difficult’ psoriasis. British Journal of Dermatology 106: 623–627 (1982).
Voorhees, J.J.: Commentary: Cyclic adenosine monophosphate regulation of normal and psoriatic epidermis. Archives of Dermatology 118: 869–874 (1982).
Ward, R.A. and Wathen, R.L.: Principles of dialysis: Utilization in nonuremic psoriatic subjects. International Journal of Dermatology 21: 154–158 (1982).
Warin, A.P.; Landells, J.W.; Levene, G.M. and Baker, H.: A prospective study of the effects of weekly oral methotrexate on liver biopsy. British Journal of Dermatology 93: 321–327 (1975).
Watson, W. and Farber, E.M.: Day-care center therapy for psoriasis. Dermatology Digest 15: 19 (1976).
Watson, W. and Farber, E.M:: Controlling psoriasis. Postgraduate Medicine 61: 103–109 (1977a).
Watson, W. and Farber, E.M.: Psoriasis Day Care Center at Stanford: Anthralin regimen; in Farber and Cox (Eds) Psoriasis. Proceedings of the Second International Symposium, pp.455–457 (Yorke Medical Books, New York 1977b).
Weigand, D.A. and Everett, M.A.: Clearing of resistant psoriasis with anthralin. Archives of Dermatology 96: 554–559 (1967).
Weinstein, G.D.; Roenigk Jr, H.H.; Maibach, H.I. and Auerbach, R.: Methotrexate guidelines —update 1981; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.395–396 (Grune and Stratum, New York 1982).
Windhorst, D.B.: Update: Retinoids in the treatment of psoriasis. Presented at The American Academy of Dermatology, Psoriasis Symposium, December 10 (1980).
Wolff, K. and Fritsch, P.O.: Retinoid —PUVA chemo-photo-chemo-therapy; in Farber and Cox (Eds) Psoriasis. Proceedings of the Third International Symposium, pp.211–219 (Grune and Stratton, New York 1982).
Young, E.: The external treatment of psoriasis: A controlled investigation of the effect of coal tar. British Journal of Dermatology 82: 516–520 (1970).
Young, E.: Ultraviolet therapy of psoriasis: A critical study. British Journal of Dermatology 87: 379–382 (1972).
Zachariae, H.; Kragballe, K. and Sogaard, H.: Methotrexate induced liyer cirrhosis. British Journal of Dermatology 102: 407–412 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farber, E.M., Nall, L. Psoriasis. Drugs 28, 324–346 (1984). https://doi.org/10.2165/00003495-198428040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198428040-00003